toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
  Record Links
Author Adeberg, S.; Harrabi, S.B.; Bougatf, N.; Bernhardt, D.; Mohr, A.; Rieber, J.; Koelsche, C.; Rieken, S.; Debus, J. url  doi
  Title Do Increased Doses to Stem-Cell Niches during Radiation Therapy Improve Glioblastoma Survival? Type Journal Article
  Year 2016 Publication Stem Cells International Abbreviated Journal Stem Cells Int  
  Volume 2016 Issue Pages 8793462  
  Abstract Background and Purpose. The reasons for the inevitable glioblastoma recurrence are yet understood. However, recent data suggest that tumor cancer stem cells (CSCs) in the stem-cell niches, with self-renewing capacities, might be responsible for tumor initiation, propagation, and recurrence. We aimed to analyze the effect of higher radiation doses to the stem-cell niches on progression-free survival (PFS) and overall survival (OS) in glioblastoma patients. Materials and Methods. Sixty-five patients with primary glioblastoma treated with radiation therapy were included in this retrospective analysis. The SVZ and DG were segmented on treatment planning magnetic resonance imaging, and the dose distributions to the structures were calculated. The relationship of dosimetry data and survival was evaluated using the Cox regression analysis. Results. Conventionally fractionated patients (n = 54) who received higher doses (D mean >/= 40 Gy) to the IL SVZ showed improved PFS (8.5 versus 5.2 months; p = 0.013). Furthermore, higher doses (D mean >/= 30 Gy) to the CL SVZ were associated with increased PFS (10.1 versus 6.9 months; p = 0.025). Conclusion. Moderate higher IL SVZ doses (>/=40 Gy) and CL SVZ doses (>/=30 Gy) are associated with improved PFS. Higher doses to the DG, the second stem-cell niche, did not influence the survival. Targeting the potential cancer stem cells in the SVZ might be a promising treatment approach for glioblastoma and should be addressed in a prospective randomized trial.  
  Address Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg, Germany; Heidelberg Institute of Radiation Oncology (HIRO), University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany  
  Corporate Author Thesis  
  Publisher Place of Publication Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume (down) Series Issue Edition  
  ISSN 1687-966X ISBN Medium  
  Area Expedition Conference  
  Notes PMID:27429623 Approved no  
  Call Number ref @ user @ Serial 96645  
Permanent link to this record
Select All    Deselect All
 |   | 

Save Citations:
Export Records: